An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy

Aimee L. McRae-Clark; Marcia L. Verduin; Bryan K. Tolliver; Rickey E. Carter; Amy E. Wahlquist; Kathleen T. Brady; Jeffrey S. Cluver; Samantha Anderson

doi:10.1080/15504260802620210

An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy

Aimee L. McRae-Clark, Marcia L. Verduin, Bryan K. Tolliver, Rickey E. Carter, Amy E. Wahlquist, Kathleen T. Brady, Jeffrey S. Cluver, Samantha Anderson

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

This open-label study evaluated the safety and efficacy of aripiprazole in the treatment of 20 patients with co-morbid schizophrenia, schizoaffective disorder, or bipolar disorder and alcohol, cocaine, and/or marijuana use disorders. Primary outcomes were substance use, measured by the Timeline Followback, and score on the Clinical Global Impression scale for psychiatric and substance use symptoms. The data suggest that aripiprazole may reduce substance use and improve psychiatric symptoms in patients with co-morbid disorders; however, limitations are noted. Subsequent randomized studies are needed to further explore these findings.

Original language	English (US)
Pages (from-to)	83-96
Number of pages	14
Journal	Journal of Dual Diagnosis
Volume	5
Issue number	1
DOIs	https://doi.org/10.1080/15504260802620210
State	Published - Jan 1 2009

Keywords

Alcohol
Aripiprazole
Cocaine
Dual diagnosis
Marijuana

ASJC Scopus subject areas

Psychiatry and Mental health

Access to Document

10.1080/15504260802620210

Cite this

@article{02c51b3c9f924e6c82a04255d351cab3,

title = "An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy",

abstract = "This open-label study evaluated the safety and efficacy of aripiprazole in the treatment of 20 patients with co-morbid schizophrenia, schizoaffective disorder, or bipolar disorder and alcohol, cocaine, and/or marijuana use disorders. Primary outcomes were substance use, measured by the Timeline Followback, and score on the Clinical Global Impression scale for psychiatric and substance use symptoms. The data suggest that aripiprazole may reduce substance use and improve psychiatric symptoms in patients with co-morbid disorders; however, limitations are noted. Subsequent randomized studies are needed to further explore these findings.",

keywords = "Alcohol, Aripiprazole, Cocaine, Dual diagnosis, Marijuana",

author = "McRae-Clark, {Aimee L.} and Verduin, {Marcia L.} and Tolliver, {Bryan K.} and Carter, {Rickey E.} and Wahlquist, {Amy E.} and Brady, {Kathleen T.} and Cluver, {Jeffrey S.} and Samantha Anderson",

year = "2009",

month = jan,

day = "1",

doi = "10.1080/15504260802620210",

language = "English (US)",

volume = "5",

pages = "83--96",

journal = "Journal of Dual Diagnosis",

issn = "1550-4263",

publisher = "Routledge",

number = "1",

}

TY - JOUR

T1 - An open-label trial of aripiprazole treatment in dual diagnosis individuals

T2 - Safety and efficacy

AU - McRae-Clark, Aimee L.

AU - Verduin, Marcia L.

AU - Tolliver, Bryan K.

AU - Carter, Rickey E.

AU - Wahlquist, Amy E.

AU - Brady, Kathleen T.

AU - Cluver, Jeffrey S.

AU - Anderson, Samantha

PY - 2009/1/1

Y1 - 2009/1/1

N2 - This open-label study evaluated the safety and efficacy of aripiprazole in the treatment of 20 patients with co-morbid schizophrenia, schizoaffective disorder, or bipolar disorder and alcohol, cocaine, and/or marijuana use disorders. Primary outcomes were substance use, measured by the Timeline Followback, and score on the Clinical Global Impression scale for psychiatric and substance use symptoms. The data suggest that aripiprazole may reduce substance use and improve psychiatric symptoms in patients with co-morbid disorders; however, limitations are noted. Subsequent randomized studies are needed to further explore these findings.

AB - This open-label study evaluated the safety and efficacy of aripiprazole in the treatment of 20 patients with co-morbid schizophrenia, schizoaffective disorder, or bipolar disorder and alcohol, cocaine, and/or marijuana use disorders. Primary outcomes were substance use, measured by the Timeline Followback, and score on the Clinical Global Impression scale for psychiatric and substance use symptoms. The data suggest that aripiprazole may reduce substance use and improve psychiatric symptoms in patients with co-morbid disorders; however, limitations are noted. Subsequent randomized studies are needed to further explore these findings.

KW - Alcohol

KW - Aripiprazole

KW - Cocaine

KW - Dual diagnosis

KW - Marijuana

UR - http://www.scopus.com/inward/record.url?scp=61649093994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61649093994&partnerID=8YFLogxK

U2 - 10.1080/15504260802620210

DO - 10.1080/15504260802620210

M3 - Article

AN - SCOPUS:61649093994

SN - 1550-4263

VL - 5

SP - 83

EP - 96

JO - Journal of Dual Diagnosis

JF - Journal of Dual Diagnosis

IS - 1

ER -

An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this